IoM seeks to augment Enzi/Kennedy bill
Executive Summary
The Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System seeks to work with Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.) on their "Enhancing Drug Safety & Innovation Act." "We certainly hope that when they start negotiations over that bill that the chair of our committee can go and testify in Congress and the bill can incorporate more of what is in the committee report," IoM Committee Study Director Kathleen Stratton said at the Academy of Managed Care Pharmacy Educational Conference Oct. 6. The committee's report, released in September, calls for sweeping changes at FDA (1The Pink Sheet" Oct. 2, 2006, p. 5)...
You may also be interested in...
FDA Drug Safety Reforms Not Enough To Fix Problems, IoM Committee Says
A separate postmarketing safety center may become necessary if the recommendations made by the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System do not result in sufficient reforms of FDA's safety oversight, the committee says
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: